- 现金
- 6172 元
- 精华
- 11
- 帖子
- 3098
- 注册时间
- 2008-7-21
- 最后登录
- 2016-1-20
|
3楼
发表于 2008-12-9 19:54
参考文献
[1] Hou J, Yin YK, Xu D, et al.. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology ,2008,47:447-454.
[2] Allice T, Cerutti F, Pittaluga F, et al. COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma. J Clin.Microbiol, 2007,45:828-834.
[3] Chevaliez S, Bouvier-Alias M, Laperche S, et al. PERFORMANCE OF THE COBAS AMPLIPREP/COBAS TAQMAN (CAP/CTM) REAL-TIME POLYMERASE CHAIN REACTION ASSAY FOR HEPATITIS B VIRUS DNA QUANTIFICATION. J Clin.Microbiol,2008,in press.
[4] Ciotti M, Marcuccilli F, Guenci T, et al. Evaluation of the Abbott RealTime HBV DNA assay and its comparison to the COBAS Ampliprep/COBAS TaqMan 48 in monitoring hepatitis B chronic patients. J Clin.Microbiol,2008, in press.
[5] Rokuhara A, Matsumoto A, Tanaka E,et al. Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy. J Gastroenterol, 2006,41:785-790.
[6] Wong DK, Yuen MF, Yuan H, et al. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology,2004,40:727-737.
[7] Singh M, Dicaire A, Wakil AE,et al. Quantitation of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) in the liver of HBV-infected patients by LightCycler real-time PCR. J Virol Methods ,2004,118:159-167.
[8] Wang Z, Zhang J, Yang H,et al. Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies. J Med Virol,2003,71:360-366.
[9] Yuen MF, Wong DK, Sum SS, et al. Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection. Am.J Gastroenterol,2005,100:1099-1103.
[10] Wong DK, Yuen MF, Ngai V W,et al. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther,2006,11:909-916.
[11] Karatayli E, Karayalcin S, Karaaslan H,et al. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther,2007,12:761-768.
[12] Chen JJ, Ma SW, Wang ZH,et al. [Kinetics of HBV mutants conferring adefovir resistance (rtn236t) and a method to detect them rapidly.] Zhonghua Ganzzangbing Zazhi,2008,16:33-37.
[13] Yang J, Xi Q, Deng R, et al. Identification of interspecies recombination among hepadnaviruses infecting cross-species hosts. J Med Virol,2007,79:1741-1750.
[14] Wang Z, Tanaka Y, Huang Y, et al. Clinical and virological characteristics of hepatitis B virus subgenotypes Ba, C1, and C2 in China. J Clin Microbiol,2007,45:1491-1496.
[15] Wang Z, Hou J, Zeng G, Wen S, et al. Distribution and characteristics of hepatitis B virus genotype C subgenotypes in China. J Viral Hepat, 2007,14:426-434.
[16] Wang Z, Liu Z, Zeng G, et al. A new intertype recombinant between genotypes C and D of hepatitis B virus identified in China. J Gen.Virol,2005,86:985-990.
[17] Chen JJ, Ma SW, Wang ZH, et al. [Affects of HBV genotypes (B/C) on the levels of serum and intrahepatic HBsAg]. Zhonghua Yixue Zazhi,2006,86:1947-1951.
[18] Sung JJ, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology, 2005,128:1890-1897.
[19] Werle-Lapostolle B, Bowden S, Locarnini S,et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology,2004,126: 1750-1758.
[20] Wursthorn K, Lutgehetmann M, Dandri M,et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology, 2006,44:675-684.
[21] Wang Z, Zhang J, Yang H, Li X,et al. Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies. J Med Virol,2003,71:360-366.
[22] Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology, 2008,47:428-434.
[23] Yen YH, Lu SN, Chen CH, et al. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy. Liver Int, 2007,27:1349-1355. |
|